Short answer
NEOGEN CORP (NEOG) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 8.01 (Other Events). Genomics sale to Zoetis remains pending, subject to regulatory approvals and customary closing conditions.
NEOGEN CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Genomics sale to Zoetis remains pending, subject to regulatory approvals and customary closing conditions
- ACCC and NZCC reviews continue, extending expected regulatory clearance to early 2027
- Zoetis offered to divest certain Australian assets to address competition concerns
- Closing delay prolongs uncertainty around proceeds, strategic separation and Neogen’s post-sale business profile
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other NEOGEN CORP 8-K filings
Get the next NEOG 8-K as it lands
Follow NEOG for push alerts, or ask the research agent what this filing means.